---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-26-000050"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2026-08-05T20:09:28+00:00"
generated_at: "2026-08-05T20:10:57.654401+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Akebia Q2 2026: Vafseo revenue $21.3M (+34% QoQ); net loss $8.9M

## Summary
- Vafseo net product revenue $21.3M in Q2 2026, up 34% from Q1; over 10,500 patients on therapy.
- Total revenue $49.1M, down 20% YoY due to Auryxia generic competition ($25.5M vs $47.2M).
- Net loss of $8.9M vs net income of $0.2M in Q2 2025; includes $1.9M restructuring charge.
- Cash $155.5M as of June 30; company expects to fund operations for at least two years.
- Initiated Phase 2 basket trial of ebribafusp for rare kidney diseases; initial data expected 2027.

## SEC filing metadata
- accession: 0001517022-26-000050
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2026-08-05T20:09:28+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702226000050/0001517022-26-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702226000050/akba-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-26-000050
- JSON: https://secwatch.observer/filing/0001517022-26-000050.json
- Plain text: https://secwatch.observer/filing/0001517022-26-000050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.